Background: Piperacillin-Tazobactam is frequently infused in hospitals. The use of a generic version was considered after the out of stock of the brand name Tazocin
Introduction
Piperacillin, an antibiotic of the penicillin family, is active against a wide range of Gram-negative organisms, including Klebsiella pneumonia, Pseudomonas aeruginosa and the enterobacteriacae. The combination of piperacillin with tazobactam, a beta-lactamase inhibitor, broadens the bactericidal activity [1] .
This antibiotic may be infused in 30 min after dilution with NaCl 0.9 % or dextrose 5 % or by extended infusion [2] .
The stability of piperacillin in combination with tazobactam has been investigated under a variety of conditions, including different concentrations (from 0.2 + 0.025 mg/ mL to 200 + 25.0 mg/mL), different diluents (5 % dextrose in water, 0.9 sodium chloride, peritoneal dialysis solution,), containers (glass, plastic bags, syringes, portable pumps), temperatures (37°C, 25°C, 4°C, −15°C, −20°C), and storage periods (from 18 hours to 98 days) [3] [4] [5] [6] [7] [8] [9] [10] .
The preparation of intravenous treatments by a Centralized IntraVenous Admixtures Service (CIVAS) contributes to the global management of treatment by providing ready-to-use injectable drugs with acceptable physicochemical and bacteriological quality and by relieving nursing staff from the tasks of infusion preparation [11] [12] [13] . The advance preparation of this antibiotic has been taken in charge on 2004 by our CIVAS [7] .
Drug shortage became a national, european and global problem [14] [15] [16] and the princeps product Tazocin ® became unavailable for a long period. At the time of the study, only one generic product was available on the Belgian market but little long term chemical data were know. Previous study investigated long-term stability of the princeps product [7] but the stability of the generic version must be determinated and compared with its of princeps. The aim of the study was to investigate the long term physico-chemical stability of this generic product of piperacillin/tazobactam in dextrose 5 % polyolefin bag after freezing, microwave thawing and final storage at 5 ± 3°C.
Materials and methods

Solutions preparation
Ten polyolefin bags (Viaflo, co-extruded layers of polyethylene, polyamide, polypropylene, Baxter, Lessines, Belgium, lot 12D27G61) of 100 mL of dextrose 5 % among which five have been supplemented with 4 g of Piperacillin/Tazobactam ® (Sandoz, Vilvoorde, Belgium, lot CG2904) reconstituted in 20 mL of injectable water and 5 other supplemented with 4 g of Tazocin ® (Pfizer, AGVG/11) reconstituted in 20 mL of injectable water were prepared under aseptic conditions to obtain a final concentration of 4 g/120 mL of piperacillin and 0.5 g/120 mL of tazobactam. The composition in excipient is not the same for the two products: Pfizer's product contain edetate disodium and citric acid monohydrate, Sandoz's product contain no excipients.
Standard solution
On each test day, a standard curve was prepared with the same commercially available powder reconstituted with purified water to obtain a 6 g/120 mL of piperacillin and 0.75 g/120 mL tazobactam stock solution. This solution is used to prepare standard curve with range concentrations of piperacillin from 0.75 g to 6 g/120 mL and tazobactam 0.09 g to 0.75 g/120 mL.
Internal standard solution 500 mg of Nafcillin (Sigma Aldrich, Germany, ref N-3269) were dissolved in a final volume of 10 mL purified water to obtain a stock solution of 50 mg/mL. Two hundred µl aliquots of this stock solution were stored at −20°C and thawed each day of the test in order to prepare two work solutions 0.5 mg/mL (for piperacillin analysis) and 0.25 mg/mL (for tazobactam analysis).
Quality control solution
The first day of the study, two control solutions were prepared with the same powder reconstituted with purified water to obtain a 4 g/120 mL piperacillin and 0.5 g/120 mL tazobactam solution and a 0.75 g/120 mL and 0.09 g/120 mL tazobactam solution. Aliquots were stocked at −80°C and one aliquot of each solution were thawed each day of the test.
Chromatographic conditions
Following a stability-indicating method as previously described [7] , a high-performance liquid chromatogra- pH determination, spectrophotometric analysis and microscope observation
Each day of the study, the pH of each solution was measured with a glass electrode pH meter (inoLab, WTW GmbH, Weilheim, Germany), the optic densities were measured with a spectrophotometer (Genesys 10 UV, Spectronic Unican) at 350 nm, 410 nm and 550 nm. Each sample was also centrifuged at 3000 rpm for 8 min to observe the pellet with an optic microscope 10 x (Carl Zeiss, Germany), looking for crystals. standardized and validated cycle, as described in a previous publication [17] . Briefly, these bags were hung to a carrousel, thawed for 13 min with an output power of 270 W then stirred and thawed again for seven minutes allowing to obtain a remaining ice volume between 1 and 8 cm 3 . The bags were then stored at 5 ± 3°C for 30 days. On each test day, 2 mL samples were withdrawn from each bag with a 2-mL polypropylene plastic syringe (Terumo, Haasrode, Belgium). The samples/controls/standards were then diluted in purified water (70-fold for piperacillin and 10-fold for tazobactam). Hundred µl of internal standard work solution 0.25 mg/mL were added to 100 µL of 70 fold diluted solution for the piperacillin analysis and 100 µL of internal standard work solution of 0.5 mg/mL were added to 100 µL of 10 -fold diluted solution.
Stability study
Ten-microliter aliquots of the prepared mixture of samples with internal standard and standard solution were injected in triplicate into the chromatographic system under the conditions previously described.
Statistical analysis
The product is considered stable as long the lower limit of the 95 % unilateral confidence of the mean concentration remains above 90 % of the initial concentration [18] or 95 % of the initial concentration when any signs of physical instability exist as recently recommend [19] .
The evolution of piperacillin and tazobactam concentrations over time where compared with linear mixed models with the molecule concentration as dependent variable, the version (generic vs princeps), the time and the time x version interaction as independent fixed variables and a random intercept for the bag. This model allows a comparison of baseline differences as well as degradation rates (or slopes) in both versions while taking into account the dependence between measures taken on the same bag.
All analyses were performed with R 3.3.2 (R Foundation of Statistical Computing, Vienna, Austria, 2016) and the ggplot2 and nlme package [20, 21] .
Results
Physical stability
No significant change in pH values or optic density was observed during the study for the princeps infusion (pH values mean 6.13 ± 0.27) or for the generic infusion (pH values mean 4.99 ± 0.37). Any crystals were seen by microscopic analysis. 
No heating
Chemical stability
There was no significant difference of degradation rate and concentration at any time between generic and princeps, and between the slopes after linear regression (p ≥ 0.795). (Table 1, Figure 6 ).
As previously described in a first stability indicating study, quality control measured at each time of the study are correct [7] .
The evolution of piperacillin and tazobactam concentration in princeps and generic versions are shown in Figure 3 . 
Mean and standard deviation (sd) of piperacillin and tazobactam in generic and princeps bags. Lower limit: lower limit of the unilateral 95 percent confidence interval on the mean. The mean, standard deviations and lower limit are expressed in percent of initial concentration. Initial concentration of piperacillin was nominally 4 g/120 mL (measured concentration 4.16 and 4.17 g/120 mL for generic and princeps respectively). Initial concentration of tazobactam was nominally 0.5 g/120 mL (measured concentration 0.42 and 0.43 g/120 mL for generic and princeps respectively). Initial concentration of piperacillin were similar between generic and princeps (4.16 vs 4.17 g/120 mL respectively, p = 0.32) while initial concentration of tazobactam were slightly different (0.42 vs 0.43 g/120 mL respectively, p = 0.0002).
The degradation rates of piperacillin and tazobactam were not significantly different between the generic and the princeps product (−0.15 %/day vs −0.13 %/day, p = 0.09 and −0.14 %/day vs −0.13 %/day, p = 0.44).
While the stability of penicillin is greatest at pH 7, and rapidly declines at pH 5.5 and below and at pH values above 8, the different values of pH for the princeps infusion (pH values mean 6.13 ± 0.27) or for the generic infusion (pH values mean 4.99 ± 0.37) does not influence the degradation rates [22] .
For both versions and both molecules, the lower limit of the 95 % unilateral confidence interval on the mean concentration remained above 90 % of the initial concentration for at least 58 days (Table 1) . These data support a stability of 58 days for both the generic and the princeps product. If one would use the more stringent limit of 95 % of the initial concentration that is sometimes recommended (REF), the stability would be of 30 days (Table 1) .
Discussion
A previous study investigated long term-stability of piperacillin/tazobactam in dextrose 5 % in polyvinyl chloride bags [7] . Peaks for decomposition products could be observed on the chromatogram without interference from the peak corresponding to the intact drug. Observed overlap did not affect either peak shape or height.
The within-day and between day coefficients of variation for replicate analysis averaged 1.0 % (n = 10) and 2.4 % (n = 20), respectively, for tazobactam and 2.4 % (n = 10) and 4.4 % (n = 20) for piperacillin, respectively.
The results of stability in polyolefin bags look similar to the previous study after freezing and microwave thawing either for princeps or generic products.
In this experiment, no differences were detected in degradation rates between the princeps and the generic product. However, we cannot rule out the existence of small differences of degradation rates between princeps and generic product.
Nowadays, the definition of supported stability is criticized. The initial definition (ICH 2003) states that a product is considered stable as long as there was enough evidence that the mean concentration remains above the acceptable limit (90 % of the initial concentration). Some authors have proposed that the definition targets a certain proportion of the samples instead of the samples mean. A product would thus be considered stable as long as the concentration of a sufficiently high proportion (say 95 %) of samples remains above the acceptable limit [23] . Under this definition, and with the help of a 95 % unilateral prediction interval, a supported stability of 51 days was obtained.
Chemical stability was only evaluated and the microbiological aspects were not investigated. However, according to the chapter 797 of the United States Pharmacopeia (USP), this preparation can be assimilated to low-risk compounding [24] .
Advance preparation of intravenous solutions by a centralized intravenous additive service might improve quality assurance, security, time management and be cost-saving for drug delivery [11, 12] . The preparation of intravenous treatments by a CIVAS contributes to the global management of treatment by providing ready-touse injectable drugs with acceptable physicochemical and bacteriological quality and by relieving nursing staff from the tasks of infusion preparation [13] .
As demonstrated for several other therapeutic infusions, freezing the solutions can extend long-term stability of ready-to-use injectable drugs [25] and microwave thawing allows to decrease the thawing time-consuming step.
Advance preparation of piperacillin/tazobactam generic infusion may be considered and added to the range of drugs reconstituted by a CIVAS [7, 17, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] .
Conclusion
Under the conditions of this study, Piperacillin/ Tazobactam ® Sandoz and Tazocin ® Pfizer 4 g/120 mL of dextrose 5 % infusion in polyolefin bags remains both stable at least for 58 days at 5 ± 3°C after freezing at −20°C and microwave thawing. Concerning the initial content or degradation rates, no substantial differences were detected between the princeps and the generic product.
This mode of preparation appears suitable for centralized pharmacy services, which could be of significant benefit to patients and of help to the nursing staff.
Advance preparation of piperacillin/tazobactam generic such as Piperacillin/Tazobactam ® Sandoz infusion may be considered and added to the range of drugs reconstituted by a CIVAS.
The conclusions of this study are limited to the studied generic form only.
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